Evidence map›Paper›PMID 35587342›Full record

ArticlePharmaceutical biology2022

Xianglong Pan, Xiaotao Hou, Fan Zhang, Peiling Tang, Wanruo Wan, Zixia Su, Yeguo Yang, Wei Wei, Zhengcai Du, Jiagang Deng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Xianglong PanGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Xiaotao HouGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Fan ZhangGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Peiling TangDepartment of Bioscience, Faculty of Applied Sciences, Tunku Abdul Rahman University College, Kuala Lumpur, Malaysia.
Wanruo WanGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Zixia SuGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Yeguo YangGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Wei WeiGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Zhengcai DuGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Jiagang DengGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Erwei HaoGuangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, Guangxi University of Chinese Medicine, Nanning, People's Republic of China.
Guangxi University · CNGuangxi University of Chinese Medicine · CNTunku Abdul Rahman University of Management and Technology · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

context

objectiveTo exam the activity and mechanism of MATERIALS AND

methodsThe anti-proliferative activity of GME (0-120 μg/mL) on SW480 cells was determined using MTS assay at 24, 48, and 72 h. The

resultsThe IC DISCUSSION AND

conclusionsGME has a significant antitumor effect on colon cancer cells SW480, and it has the potential to be developed as an anticancer agent.

Indexed as

Colonic NeoplasmsGnetumAnimalsApoptosisCaspase 3Cell Line, TumorCell ProliferationGlycogen Synthase Kinase 3 betaHumansMiceMice, NudePlant ExtractsProto-Oncogene Proteins c-aktTandem Mass SpectrometryZebrafishCaspase 3Glycogen Synthase Kinase 3 betaPlant ExtractsProto-Oncogene Proteins c-aktAKT signalling pathwaycell cyclechemical compositionflow cytometrysynergistic anticancer activityYao medicinezebrafish

Identifiers

PMID35587342
PMCPMC9122364
OpenAlexW4280527716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.